Trial Profile
A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Mar 2023
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Registrational; Therapeutic Use
- Sponsors Mylan
- 11 Oct 2021 Status changed from active, no longer recruiting to completed.
- 29 Sep 2020 Planned End Date changed from 21 Dec 2020 to 15 Sep 2021.
- 29 Sep 2020 Planned primary completion date changed from 28 Feb 2020 to 15 Nov 2020.